stockrow
Friday 6 November 2026
Export AIM’s income statement to Excel — free account
AIM ImmunoTech Inc.
AIM ImmunoTech Inc.’s revenue for fiscal 2025 (year ended December 2025) was $88,000.00, down 48.2% from fiscal 2024.
- Revenue
- +4.00%
- EPS
- +88.3%
- Free cash flow
- −167.5%
Quarter to June 2026, against a year earlier
0.16
0.01
+6.67%
Follow AIM
Alert me
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
3 | 3 | 2 | 2 |
| 995.26% | 251.38% | 1,533.03% | (2,382.30%) | ||
| (165.08%) | (194.00%) | (179.01%) | (169.28%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
1,134.73% | 488.38% | (10,134.35%) | (257.58%) | |
Average Days of Receivables |
0.00 | 29.03 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(6.37) | (3.88) | (2.68) | (0.85) | |
Free Cash Flow |
(13.33) | (11.33) | (11.67) | (14.62) | |
Capital Expenditures |
(0.40) | (0.38) | (0.36) | (0.24) | |
| Other line items | |||||
Cash ROIC |
363.36% | 195.13% | (142.10%) | (82.54%) | |
Accounts Receivable Turnover |
0.00 | 4.40 | 0.00 | 0.00 | |
Accounts Payable Turnover |
0.03 | 0.03 | 0.03 | 0.03 | |
Inventory Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
4,810.32 | 4,648.05 | 3,635.04 | 1,497.44 | |
Days of Inventory on Hand |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
4,040.18% | 4,459.09% | 3,538.30% | 2,885.26% | |
Selling, General and Administrative Expense of Revenue |
8,981.25% | 8,750.00% | 7,358.51% | 8,815.79% | |
Share Based Compensation of Revenue |
228.57% | 68.18% | 0.00% | 0.00% | |
Interest Coverage |
(26.34) | (14.36) | (10.35) | (9.79) | |
Operating CF/Net income |
0.82 | 0.79 | 0.85 | 1.01 | |
Depreciation/Fixed assets |
15.64 | 26.76 | 26.92 | 27.83 | |
Capex/Depreciation |
(0.32) | (0.20) | (0.21) | (0.16) | |
Revenue per Share |
0.05 | 0.03 | 0.02 | 0.01 | |
Operating CF per Share |
(6.18) | (3.75) | (2.60) | (0.84) | |
Capex per Share |
(0.19) | (0.13) | (0.08) | (0.01) | |
Capex to Sales |
3.59 | 4.30 | 3.80 | 2.55 |
Columns are period end dates · fundamentals updated 26 Oct 2026